Mar 27, 2026
BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient SettingVIEW RELEASE
Mar 11, 2026
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct OfferingVIEW RELEASE
Mar 10, 2026
BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct OfferingVIEW RELEASE
Stock Information
BioXcel Therapeutics, Inc.
Mar 30, 2026 12:15 PM
MARKET/SYMBOL
Nasdaq:
BTAI
PRICE
1.2
CHANGE
-0.06 (-4.76%)